Compare · RGC vs XXII
RGC vs XXII
Side-by-side comparison of Regencell Bioscience Holdings Limited (RGC) and 22nd Century Group Inc. (XXII): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RGC and XXII operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $2.48B, about 7.5x XXII ($332.0M).
- XXII has hit the wire 5 times in the past 4 weeks while RGC has been quiet.
- XXII has more recent analyst coverage (4 ratings vs 0 for RGC).
- Company
- Regencell Bioscience Holdings Limited
- 22nd Century Group Inc.
- Price
- -
- -
- Market cap
- $2.48B
- $332.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- AMEX
- IPO
- 2021
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 4
22nd Century Group Inc.
22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
Latest RGC
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
Latest XXII
- 22nd Century Group (Nasdaq: XXII) Appoints Katherine Rouse-Bailey as Vice President of Marketing
- SEC Form 8-K filed by 22nd Century Group Inc.
- SEC Form 424B3 filed by 22nd Century Group Inc.
- SEC Form EFFECT filed by 22nd Century Group Inc.
- SEC Form DEF 14A filed by 22nd Century Group Inc.
- SEC Form PRE 14A filed by 22nd Century Group Inc.
- SEC Form S-3 filed by 22nd Century Group Inc.
- 22nd Century Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: 22nd Century Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- 22nd Century Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits